

## **2019 Annual Conference**

**June 5-8, 2019**  
**“Transplant 2019: Moving Beyond Toxicity”**  
Learning Objectives

---

### **BMT101A: Health Care Professionals**

1. Summarize topics in the field of hematopoietic stem cell transplant and cellular therapy
2. Identify updates in cellular therapies and stem cell biology as it relates to stem cell transplantation
3. Identify strategies for managing and avoiding complications of transplant

### **Session 1: Hans Messner Lectureship**

1. Summarize updates in late-breaking and cell therapy
2. Discuss the implementation of CAR-T cell therapy in BMT centres across Canada
3. Analyze the evolving fields of hematopoietic stem cell transplant and cellular therapy, including recent new indications and therapies post-transplant

### **Session 2A: Science**

1. Summarize a novel classification of target antigens for T-cell based immunotherapy of cancer
2. Identify updates in state of the art and emerging treatments for acute lymphoblastic leukemia
3. Describe how therapeutic modalities can contribute to T-cell based immunotherapy of acute myeloid leukemia

### **Session 2B: Laboratory: Technologists and Technology – You can’t have one without the other!**

1. Explain novel cell and immunotherapy product processing from a laboratory perspective
2. Identify strategies for increasing efficiency and quality assurance with electronic records
3. Explore what is currently available as potency tests for stem cells, and the associated challenges

### **Session 2C: Allied Health**

1. Discuss pediatric specific complications from an allied health perspective
2. Identify strategies to assist with transitioning patients from pediatric to adult care
3. Discuss the value of survivorship clinics for screening and monitoring post BMT
4. Summarize cardiac complications post-hematopoietic stem cell transplant

### **Session 2D: Allied Health**

1. Describe the latest evidence for fertility protection and/or preservation in women undergoing transplant
2. Examine cannabis use with hematopoietic stem cell transplant
3. Explain survivorship from a hematopoietic stem cell transplant patient perspective

### **Session 3: Fred Saunders Lectureship**

1. Describe the leading causes of late mortality in HCT survivors.
2. Explain the risk factors for the development of cardio-metabolic conditions after HCT and what should be done for screening in long-term follow-up.
3. Describe risk factors for subsequent malignancy risk in children after HCT and how patients should be monitored in long-term follow-up.

### **Session 4: Managing and Preventing Adverse Psychosocial Complications**

1. Identify strategies for managing and preventing adverse psychosocial complications
2. Summarize strategies for early integration of palliative care
3. Understand sexual health post- hematopoietic stem cell transplant

### **Session 5: Controversies in Autologous Transplants: An Adult & Pediatric Panel Discussion**

1. Summarize the evolving field of autologous and allogeneic transplant
2. Explain the controversies in autologous transplant from both an adult and pediatric perspective
3. Identify new strategies for managing autoimmune disease

### **Session 6: DEBATE: CAR-T Cells vs. Allogeneic Transplant for Patients with Relapsed ALL**

1. Critique the different approaches for managing patients with relapsed Acute Lymphoblastic Leukemia
2. Describe CAR-T cell therapy for relapsed Acute Lymphoblastic
3. Summarize allogeneic transplant for relapsed Acute Lymphoblastic